A UCLA-led team has discovered that using early-stage stem cells is a key to producing structures that are reliable models of disease.
A new study in mice suggests that adding iNKT cells to a stem cell transplant could reduce complication severity.
The research is an important advance toward cell therapies that could restore sensation in people with spinal cord injuries.
The study could eventually lead to more treatment options for leukemia, sickle cell disease and other conditions.
A gift from the Alfred E. Mann Family Foundation will support research at the Broad Stem Cell Research Center and California NanoSystems Institute.
After more than two years, Marley Gaskins, the first child to receive the innovative treatment for LAD-1, remains disease-free.
Meet the new director of the UCLA Broad Stem Cell Research Center.
Research brief: Adding a protein called viral polymerase to vaccines could potentially create a more robust, enduring immune response, scientists say.
Research brief: A UCLA-led study identifies a potential target for therapies to prevent or treat heart failure.
Using stem cell engineering and organoid technology, UCLA researchers were able to produce large quantities of powerful cancer-fighting iNKT cells.
UCLA researchers use super-resolution microscopy to reveal surprising new details about X inactivation in female mouse embryos.
Researchers report that all nine patients who were successfully treated for ADA-SCID in a UCLA clinical trial from 2009 to 2012 are still disease-free.
“We need to figure out how this is happening in order to develop treatments to stop it,” said UCLA’s Arjun Deb.
The five-year award from California’s stem cell agency will help prepare young scientists and physicians to become leaders in the regenerative medicine field.
A UCLA study suggests researchers could analyze neurological disorders in a stem cell–derived model.
The renowned neurologist and stem cell biologist is currently a professor at Stanford University.
UCLA researchers discover that MAOIs could activate immune system to shrink various types of tumors.
The treatment, developed by researchers from UCLA and the U.K., has restored immune function in more than 95% of patients in three clinical trials.
A UCLA study identifies a cell therapy that can stop progressive damage and stimulate the brain’s repair processes in mice.
Research brief: A UCLA team has demonstrated that altering a key molecule used in the therapy yields superior and longer-lasting results in mouse models.
The project is the first to use the Nobel prize–winning technology to directly correct sickle mutation in blood stem cells.
Professors Robert Damoiseaux and Vaithilingaraja Arumugaswami led a collaboration among scientists from the U.S. and Germany.
The advance could be a step toward the development of treatments for muscle loss or damage due to injury, age or disease.
UCLA’s Dr. Arjun Deb said the same model could also help researchers learn more about other similar viruses that might emerge in the future.
“It’s too early to declare victory, but it’s looking quite promising at this point,” said UCLA’s Dr. Donald Kohn.